Rituximab May Be More Effective in Early-Onset Myasthenia Gravis

This retrospective cohort study suggests that rituximab is more effective than conventional immunotherapy and might most impactful if initiated within 12 months of symptom onset in myasthenia gravis.

from Front page feed https://ift.tt/2T10jNg